573 related articles for article (PubMed ID: 28550482)
1. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
3. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
[TBL] [Abstract][Full Text] [Related]
5. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Marconi S; Zwingers T
Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1879-82. PubMed ID: 25010617
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265
[TBL] [Abstract][Full Text] [Related]
8. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
9. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
Binde CD; Tvete IF; Gåsemyr J; Natvig B; Klemp M
Br J Clin Pharmacol; 2018 Sep; 84(9):1917-1927. PubMed ID: 29847694
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study.
Peretz C; Segev H; Rozani V; Gurevich T; El-Ad B; Tsamir J; Giladi N
Clin Neuropharmacol; 2016; 39(5):227-31. PubMed ID: 27438181
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Müller T; Riederer P; Grünblatt E
J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
[TBL] [Abstract][Full Text] [Related]
12. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E; Stern MB
Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
[TBL] [Abstract][Full Text] [Related]
14. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
15. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
[TBL] [Abstract][Full Text] [Related]
16. Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in Parkinson's disease are dependent on frontal function.
Murakami H; Okumura M; Ozawa M; Mimori M; Maku T; Shiraishi T; Kitagawa T; Takatsu H; Sato T; Komatsu T; Sakai K; Umehara T; Omoto S; Mitsumura H; Iguchi Y
Neurol Sci; 2023 Mar; 44(3):913-918. PubMed ID: 36376554
[TBL] [Abstract][Full Text] [Related]
17. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
18. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
19. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
Chen JJ; Fernandez HH
Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
[TBL] [Abstract][Full Text] [Related]
20. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]